Development of a Probiotic-Infused Carbamazepine Dosage Form.

Area of Science:

• Pharmaceutical Sciences
• Microbiology
• Toxicology

Background:

• Carbamazepine is a widely used antiepileptic drug.
• Probiotics, like Bifidobacterium bifidum, offer potential health benefits.
• Combining active pharmaceutical ingredients in a single dosage form presents formulation challenges and opportunities.

Purpose of the Study:

• To develop and evaluate a novel dosage form combining carbamazepine with Bifidobacterium bifidum.
• To assess the stability and safety of the combined formulation.
• To investigate the effects of the combined dosage form on anxiety, weight, and urination in a preclinical model.

Main Methods:

• Agar disk diffusion was used to determine probiotic susceptibility to carbamazepine.
• A carbamazepine-probiotic suspension was formulated using the precipitation method.
• Stability testing included organoleptic properties, pH, and bacterial viability.
• Toxicity was assessed in Wistar rats, monitoring weight, urination, and anxiety.

Main Results:

• Bifidobacterium bifidum demonstrated resistance to carbamazepine.
• The combined carbamazepine-Bifidobacterium bifidum formulation significantly reduced anxiety (P=0.0312) and weight (P=0.03186) while increasing urination.
• The dosage form remained stable for 28 days, maintaining bacterial viability.

Conclusions:

• Integrating probiotics into carbamazepine formulations is a promising strategy.
• This approach may offer therapeutic advantages for managing epilepsy and related symptoms.
• The findings suggest potential applications for probiotic-drug combinations in other antiepileptic therapies.